ProQR Therapeutics is a clinical stage biopharmaceutical company. Co. is developing a pipeline of RNA therapies for inherited retinal diseases. Beyond its clinical portfolio, Co. has discovered and developed two proprietary RNA editing platform technologies, Axiomer and TRIDENT. Co.'s editing oligonucleotides are designed to recruit endogenous Adenosine Deaminases Acting on RNA, enzymes to make single nucleotide changes in the RNA in a manner at a desired location. TRIDENT is Co.'s RNA pseudouridylation platform that enables the selective suppression of nonsense mutations that cause human genetic disease. The PRQR average annual return since 2014 is shown above.
The Average Annual Return on the PRQR average annual return since 2014 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether PRQR average annual return since 2014 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the PRQR average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|